Chime Financial Confirms Strong 2025 Performance with Audited Results, Reports Positive Adjusted EBITDA
CHYM sits 38% above its 52-week low of $16.17.
Summary
Chime Financial's 2025 annual report confirms strong revenue and member growth, with Adjusted EBITDA turning positive. A large net loss was primarily due to IPO-related stock compensation, and the company initiated a significant share repurchase program.
Key Events · Earnings and Guidance · CHYM
-
Full Year 2025 Revenue Growth
Revenue increased 31% year-over-year to $2.19 billion, driven by growth in active members and new product launches.
-
Adjusted EBITDA Turns Positive
The company achieved a positive Adjusted EBITDA of $126.6 million in 2025, a significant improvement from a loss in the prior year, reflecting enhanced operational performance.
-
Net Loss Driven by IPO-Related Stock Compensation
A net loss of $1.01 billion was reported, largely due to $1.09 billion in non-cash stock-based compensation expense from equity awards vesting upon the June 2025 IPO.
-
Strong Member and Purchase Volume Growth
Active members grew 19% to 9.5 million, and purchase volume increased 16% to $133.7 billion, indicating robust user engagement.
Analysis · CHYM · Finance
Chime Financial's 2025 annual report confirms robust operational performance, with revenue increasing 31% to $2.19 billion and active members growing 19% to 9.5 million. A significant highlight is the shift to a positive Adjusted EBITDA of $126.6 million, indicating improved underlying profitability and operational efficiency. While the company reported a net loss of $1.01 billion, this was primarily driven by a substantial $1.09 billion in non-cash stock-based compensation expense related to the vesting of equity awards upon its June 2025 IPO. The company also initiated a $200 million share repurchase program in November 2025, having already repurchased $77.5 million by year-end, signaling management confidence. Investors should note the 85% increase in transaction and risk losses, primarily from liquidity products and isolated fraud incidents, which warrants continued monitoring.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHYM was trading at $22.31 on NASDAQ in the Finance sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $16.17 to $44.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.